Vaccine trial aims to stop breast cancer before it starts
NCT ID NCT06218303
Summary
This study is testing whether adding a vaccine to standard hormone therapy can help prevent breast cancer in women with ductal carcinoma in situ (DCIS), which are abnormal cells that haven't spread. Women will receive either hormone therapy alone or hormone therapy plus a vaccine before their scheduled surgery. The goal is to see if the vaccine helps the immune system recognize and eliminate these abnormal cells to prevent them from becoming invasive cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCTAL CARCINOMA IN SITU are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Magee Womens Hospital
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.